Turning Point Brands is funding a high-growth nicotine pouch transition from legacy cash flows, with domestic manufacturing offering substantial upside but meaningful regulatory and competitive execution risk.
Overview
Turning Point Brands is a branded, asset-light alternative tobacco and nicotine company built around two segments: Stoker’s, which includes traditional smokeless products and Modern Oral pouches, and Zig-Zag, which sells premium rolling papers and accessories. Approximately 75% of production is outsourced, supporting capital efficiency and strategic flexibility, while distribution reaches more than 215,000 North American outlets. **The investment case is a cash-to-pouch transformation:** legacy Stoker’s and Zig-Zag cash flows are funding the higher-growth FRĒ and ALP nicotine pouch platforms. Q2 2026 net sales rose 22.6% year over year to $142.96 million, with Modern Oral net sales up 128% to $68.40 million, or 48% of consolidated sales. Management raised 2026 Modern Oral net-sales guidance to $260 million–$270 million and gross-sales guidance to $330 million–$350 million, while maintaining $70 million–$90 million of adjusted EBITDA guidance. Near-term profitability is pressured by commercialization spending, with Q2 adjusted EBITDA down 50% to $15.24 million. **The primary catalyst is domestic pouch manufacturing**, expected to qualify by mid-2027 or early 2027 and ultimately support approximately 70% category gross margins. At $86.86, the probability-weighted five-year target is $125.75, but regulatory and competitive risks remain material.